Streptococcus thermophilus NCIMB 41856 ameliorates signs of colitis in an animal model of inflammatory bowel disease

<jats:p>Treatment of inflammatory bowel disease (IBD) is mainly based on suppression of symptoms, often with numerous side effects. Trials of probiotics in IBD have frequently produced disappointing results. The majority of probiotics are unusual, since they do not require iron for growth, unlike many bacteria resident in the intestine. The IBD intestine is iron-rich due to bleeding and use of oral iron supplements; conventional probiotics would be rapidly outcompeted. We have evaluated an iron-responsive <jats:italic>Streptococcus thermophilus</jats:italic> strain for its potential to reduce signs of colitis. Efficacy of <jats:italic>S. thermophilus</jats:italic> was evaluated in the dextran sodium sulphate mouse model of colitis. Treated animals were given 1×10<jats:sup>8</jats:sup> cfu <jats:italic>S. thermophilus</jats:italic> per day and clinical observations were taken daily. At termination, gross and histopathological signs of disease, cellular infiltration, location of bacteria, and cytokine expression in the intestine were determined. <jats:italic>S. thermophilus</jats:italic> delayed onset of colitis and reduced clinical signs of disease, including bodyweight loss and gastrointestinal bleeding. It reduced bacterial translocation into the colonic tissue. Increased numbers of CD8<jats:sup>+</jats:sup> intraepithelial lymphocytes were seen in control animals treated with <jats:italic>S. thermophilus</jats:italic>. <jats:italic>S. thermophilus</jats:italic> had no effect on gross pathology, histopathology or cytokine production in either colitic or control animals. We propose that <jats:italic>S. thermophilus</jats:italic> promotes maintenance of mucosal barrier function which reduces bacterial translocation, thereby reducing immune stimulation and associated inflammation. This allows mucosal healing, reducing gastrointestinal bleeding and weight loss. This could be studied as a locally-acting adjunct or alternative to current IBD treatments.</jats:p>